Current concepts in malignant bowel obstruction management

Malignant bowel obstruction (MBO) is a challenging complication of advanced cancer. Several pathophysiologic mechanisms are responsible for the syndrome, including mechanical compression, motility disorders, gastrointestinal secretion accumulation, decreased gastrointestinal absorption, and inflammation. The treatment of related symptoms requires a collaborative approach of surgical, interventional, and medical specialists. The surgical approach proves beneficial in selected patients with operable lesions, life expectancy greater than 2 months, and good performance status. Interventionalists place self-expanding metallic stents as a minimally invasive palliative method either as a definitive treatment or as a bridge to surgery. However, most patients with MBO are not candidates for surgery or stent placement. Medical management with opioids, antispasmodics, anti-emetics, antisecretory agents, and corticosteroids is effective in controlling the symptoms associated with MBO. This article discusses the current understanding of MBO pathophysiology and emphasizes current MBO management concepts; it then reviews surgical, interventional, and medical approaches.

[1]  L. Lagasse,et al.  Intestinal operations in patients with ovarian carcinoma. , 1981, American Journal of Obstetrics and Gynecology.

[2]  R. Clarke Nausea and vomiting. , 1986, British journal of anaesthesia.

[3]  R. L. Carter,et al.  MEDICAL MANAGEMENT OF INTESTINAL OBSTRUCTION IN PATIENTS WITH ADVANCED MALIGNANT DISEASE A Clinical and Pathological Study , 1985, The Lancet.

[4]  M. Stoler,et al.  Distribution of disease at autopsy in 100 women with ovarian cancer. , 1988, Human pathology.

[5]  A. Caraceni,et al.  The Management of Inoperable Gastrointestinal Obstruction in Terminal Cancer Patients , 1990, Tumori.

[6]  I. Leitman,et al.  Multivariate analysis of morbidity and mortality from the initial surgical management of obstructing carcinoma of the colon. , 1992, Surgery, gynecology & obstetrics.

[7]  N. Petrelli,et al.  Bowel rest, intravenous hydration, and continuous high‐dose infusion of octreotide acetate for the treatment of chemotherapy‐induced diarrhea in patients with colorectal carcinoma , 1993, Cancer.

[8]  F. De Conno,et al.  Management of bowel obstruction in advanced and terminal cancer patients. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Twycross Pain relief in advanced cancer , 1994 .

[10]  C. Ripamonti Management of bowel obstruction in advanced cancer. , 1994, Current opinion in oncology.

[11]  M. Cunningham,et al.  Percutaneous gastrostomy for decompression in patients with advanced gynecologic malignancies. , 1995, Gynecologic oncology.

[12]  H. Li,et al.  [Management of intestinal obstruction in advanced ovarian cancer an analysis of 57 cases]. , 1995, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[13]  M. Baines ABC of palliative care: Nausea, vomiting, and intestinal obstruction , 1997 .

[14]  M. Gore,et al.  Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction , 1998, Palliative medicine.

[15]  J. Muir ABC of Palliative Care , 1999, Annals of Internal Medicine.

[16]  Colin D. Johnson,et al.  Quality of life in stoma patients , 1999, Diseases of the colon and rectum.

[17]  J. Shepherd,et al.  Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. , 1999, Gynecologic oncology.

[18]  C. V. von Gunten,et al.  Antisecretory agents in gastrointestinal obstruction. , 2000, Clinics in geriatric medicine.

[19]  E. Zecca,et al.  Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. , 2000, Journal of pain and symptom management.

[20]  W. Tierney,et al.  Outcomes of Percutaneous Endoscopic Gastrostomy Among Older Adults in a Community Setting , 2000, Journal of the American Geriatrics Society.

[21]  K. Broadley,et al.  Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. , 2000, The Cochrane database of systematic reviews.

[22]  R. Johannes,et al.  Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. , 2001, Gastrointestinal endoscopy.

[23]  C. Ripamonti,et al.  The Role of Somatostatin and Octreotide in Bowel Obstruction: Pre-Clinic Al and Clinical Results , 2001, Tumori.

[24]  N. Marcon,et al.  A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction , 2001, American Journal of Gastroenterology.

[25]  F. De Conno,et al.  Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer , 2001, Supportive Care in Cancer.

[26]  P. Ortega-Deballon,et al.  Self-Expandable Stent Before Elective Surgery vs. Emergency Surgery for the Treatment of Malignant Colorectal Obstructions: Comparison of Primary Anastomosis and Morbidity Rates , 2002, Diseases of the colon and rectum.

[27]  L. Hynan,et al.  Emergency Surgery for Colon Carcinoma , 2003, Diseases of the colon and rectum.

[28]  Masashi Uramatsu,et al.  Long-Term Prognosis of Preoperative “Bridge to Surgery” Expandable Metallic Stent Insertion for Obstructive Colorectal Cancer: Comparison with Emergency Operation , 2003, Diseases of the colon and rectum.

[29]  W. Law,et al.  Comparison of stenting with emergency surgery as palliative treatment for obstructing primary left‐sided colorectal cancer , 2003, The British journal of surgery.

[30]  B. Liedman,et al.  Palliation of Malignant Gastroduodenal Obstruction with Open Surgical Bypass or Endoscopic Stenting: Clinical Outcome and Health Economic Evaluation , 2004, World Journal of Surgery.

[31]  S. Mercadante,et al.  How to use octreotide for malignant bowel obstruction. , 2004, The journal of supportive oncology.

[32]  S. Sebastian,et al.  Pooled Analysis of the Efficacy and Safety of Self-Expanding Metal Stenting in Malignant Colorectal Obstruction , 2004, American Journal of Gastroenterology.

[33]  M. Franchi,et al.  Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis , 2004, International Journal of Gynecologic Cancer.

[34]  P. Fockens,et al.  Premature closure of the Dutch Stent-in I study , 2006, The Lancet.

[35]  Colonic stenting as bridge to surgery versus emergency surgery for management of acute left-sided malignant colonic obstruction: a multicenter randomized trial (Stent-in 2 study) , 2007, BMC surgery.

[36]  N. Khandelwal,et al.  Colonic stent versus surgery for the management of acute malignant colonic obstruction: a decision analysis , 2007, Alimentary pharmacology & therapeutics.

[37]  H. Gerdes,et al.  Management of malignant bowel obstruction. , 2008, European journal of cancer.

[38]  Y. Sasaki,et al.  Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. , 2008, Japanese journal of clinical oncology.

[39]  M. Freeman,et al.  Enteral and colonic self-expanding metallic stents. , 2008, Reviews in gastroenterological disorders.

[40]  E. Bruera,et al.  Textbook of Palliative Medicine , 2009 .

[41]  Nicholas A. Christakis,et al.  Oxford Textbook of Palliative Medicine , 2011 .